Presented by Peter R. Carroll, MD, MPH, Professor and Chair, Department of Urology, University of California, San Francisco, San Francisco, California, and Andrew J. Vickers, PhD, Attending Research Methodologist, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York City, and Professor of Medicine, Weill Medical College of Cornell University, New York City, New York.
J Natl Compr Canc Netw. 2014 May;12(5 Suppl):768-71. doi: 10.6004/jnccn.2014.0186.
Few clinical issues have polarized the oncology community as much as screening for prostate cancer, with advocates of prostate-specific antigen (PSA) testing vocal on one side and skeptics just as vocal on the other. At the NCCN 19th Annual Conference, Dr. Peter R. Carroll and Dr. Andrew J. Vickers tackled the controversy surrounding early detection of prostate cancer, focusing attention on the randomized trial results at the heart of the matter; over-detection (the Achilles' heel of screening); and the rationale behind the new, streamlined 2014 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection, which emphasize selective early detection and treatment and are tightly aligned with the NCCN Guidelines for Prostate Cancer.
在肿瘤学界，很少有临床问题像前列腺癌筛查那样两极分化，支持前列腺特异性抗原（PSA）检测的一方声音响亮，而持怀疑态度的一方也同样响亮。在 NCCN 第 19 届年会上，Peter R. Carroll 博士和 Andrew J. Vickers 博士探讨了围绕前列腺癌早期检测的争议，重点关注了核心问题的随机试验结果；过度检测（筛查的阿喀琉斯之踵）；以及新的、精简的 2014 年 NCCN 肿瘤学临床实践指南（NCCN 指南）中前列腺癌早期检测背后的基本原理，该指南强调有选择性的早期检测和治疗，与 NCCN 前列腺癌指南紧密一致。
Zotero 插件